A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Take CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA), two biotechs specializing in gene editing. Finance, is $83.60; the latter earns a price target of $50.80 from ...

CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and ...

Bayer is to set up a joint venture with CRISPR Therapeutics and acquire a minority stake in the firm, one of the pioneers in the potentially revolutionary gene-editing technology. The partnership ...